Both companies may succeed in this industry.

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

This biotech has candidates in late-stage clinical development.

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech Abivax and had no contact with U.S. pharmaceutical giant Eli Lilly, ...

Both companies now aim to win in the oral weight loss drug market.

One of the major promises of artificial intelligence (AI) is its role in speeding up drug discovery. AI can process massive amounts of data far faster than humans, identifying potential drug ...

Yahoo Finance Senior Reporter Brooke DiPalma tracks Monday's top moving stocks and biggest market stories in this Market Minute. Taiwan Semiconductor Manufacturing Company (TSM) stock is moving higher ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...